Waldenström macroglobulinemia (WM) is a usually slow-growing non-Hodgkin lymphoma characterized by lymphoplasmacytic cancer cells in the bone marrow and a monoclonal immunoglobulin M (IgM) protein in the blood. Its manifestations arise both from the accumulation of abnormal cells and from the physical or immune effects of the IgM they produce. Some people have no symptoms at diagnosis, whereas others develop anemia, bleeding, neurological symptoms, or impaired circulation caused by increased blood viscosity.
Classification and biological basis
WM is the IgM-secreting form of lymphoplasmacytic lymphoma, a malignancy of mature B cells. The abnormal population includes small lymphocytes, cells with intermediate lymphocyte and plasma-cell features, and plasma cells. These related cells belong to a clone derived from a common precursor.
IgM is a large antibody normally involved in immune defense. In WM, the clone produces an excessive amount of one IgM molecule, termed a monoclonal protein or paraprotein. The historical word “macroglobulinemia” refers to the presence of this large immunoglobulin in the blood.
Two biological processes account for much of the disease:
- Tissue infiltration: abnormal cells occupy marrow and sometimes accumulate in lymph nodes, the spleen, or other tissues.
- IgM-mediated effects: circulating IgM can increase serum viscosity, react with blood cells or nerves, precipitate at low temperatures, or contribute to tissue deposits.
The amount of circulating IgM does not reliably measure every aspect of the disease. A relatively small clone can produce an IgM protein with substantial biological effects, while some people with a high IgM concentration have few symptoms.
Molecular features and causes
An acquired mutation in the MYD88 gene, most commonly L265P, is found in approximately 90% or more of WM cases, depending on the population and testing method. It promotes signaling that supports malignant-cell survival, including pathways involving Bruton tyrosine kinase.
Mutations in CXCR4 occur in roughly one-third of cases. They can influence disease characteristics and the speed or depth of response to some treatments. Neither mutation alone establishes the diagnosis: MYD88 mutations also occur in some related conditions, and a minority of well-characterized WM cases lack the common mutation.
The initiating cause is usually unknown. Familial clustering of WM and related B-cell disorders supports an inherited susceptibility in some families, but most cases are sporadic. The mutations detected in the tumor are generally acquired rather than inherited.
Epidemiology and history
WM is rare, with an annual incidence of approximately three to four cases per million people in the United States. It predominantly affects older adults, with diagnosis typically occurring around the seventh decade of life, and is more common in men. Reported incidence differs among populations and geographic regions.
The disorder is named after the Swedish physician Jan Waldenström, who described patients with bleeding, anemia, and an unusually large serum globulin in 1944. Later work established its relationship to lymphoplasmacytic lymphoma and identified the abnormal protein as monoclonal IgM.
Clinical manifestations
Marrow and tissue involvement
Marrow infiltration can reduce normal blood-cell production. Anemia is a common manifestation and may cause fatigue, weakness, or shortness of breath. Reduced platelet counts can contribute to bruising or bleeding. Some patients have enlarged lymph nodes, an enlarged spleen, or an enlarged liver.
Weight loss, fever, and night sweats may occur, although their presence is not specific to WM.
Hyperviscosity
Excess circulating IgM can produce hyperviscosity syndrome, in which abnormal resistance to blood flow impairs microcirculation. Manifestations include:
- Nosebleeds or other mucosal bleeding.
- Blurred vision and retinal abnormalities.
- Headache, dizziness, or altered mental status.
Symptomatic hyperviscosity is a medical emergency. Its occurrence depends on the properties of the IgM protein as well as its concentration; no single IgM value predicts symptoms in every patient.
Other IgM-related effects
Peripheral neuropathy can cause numbness, tingling, impaired balance, or weakness. In some cases, the monoclonal IgM reacts with myelin-associated glycoprotein or other nerve components.
Other complications include:
- Cold agglutinin activity: IgM reacts with red blood cells at lower temperatures and can cause hemolysis.
- Cryoglobulinemia: immunoglobulins precipitate in the cold and may produce skin, vascular, nerve, or renal manifestations.
- Amyloidosis: abnormal protein deposits can damage organs.
- Acquired bleeding abnormalities: interference with clotting proteins or platelet function can increase bleeding.
Kidney involvement is less common than in multiple myeloma but can result from several distinct mechanisms. Rarely, lymphoplasmacytic cells infiltrate the central nervous system, producing Bing–Neel syndrome. This is distinct from neurological symptoms caused by hyperviscosity.
Diagnosis and differential diagnosis
Diagnosis rests on demonstrating both a serum monoclonal IgM protein and marrow involvement by lymphoplasmacytic lymphoma. An IgM paraprotein alone is insufficient.
The evaluation commonly includes:
- A complete blood count and tests of kidney and liver function.
- Serum protein electrophoresis, immunofixation, and quantitative immunoglobulin measurements.
- Bone marrow aspiration and biopsy, with examination of cell morphology and immunophenotype.
- Molecular testing for MYD88 and, in relevant settings, CXCR4 mutations.
- Serum viscosity measurement and retinal examination when hyperviscosity is suspected.
- Imaging when needed to assess lymph-node enlargement, organ involvement, or possible transformation.
Diagnostic classification systems differ somewhat in the minimum marrow infiltration required to distinguish WM from precursor states. Interpretation therefore combines the marrow findings, immunophenotype, molecular results, and clinical context rather than relying solely on an IgM concentration or a single genetic test.
The differential diagnosis includes:
- IgM monoclonal gammopathy of undetermined significance: a precursor condition without sufficient evidence of overt lymphoma.
- Other B-cell lymphomas with plasmacytic differentiation: particularly marginal zone lymphoma.
- IgM multiple myeloma: a rare plasma-cell malignancy with different pathological and molecular features.
- IgM-related disorders: conditions in which the monoclonal protein causes organ damage without diagnostic marrow involvement by WM.
Asymptomatic, or smoldering, WM denotes established disease without symptoms or organ injury attributable to it.
Management
Management distinguishes asymptomatic disease from disease causing clinically important complications. Observation with periodic assessment is standard for many asymptomatic patients. A monoclonal IgM concentration alone is generally not sufficient to determine the need for treatment, although exceptionally high levels can influence evaluation and management.
Treatment is used for disease-related problems such as symptomatic cytopenias, hyperviscosity, significant neuropathy, symptomatic tissue enlargement, or other attributable organ damage.
Systemic treatment
Common treatment approaches include:
- Rituximab-based combinations. Rituximab is a monoclonal antibody directed against CD20. It may be combined with bendamustine or with cyclophosphamide and dexamethasone.
- Bruton tyrosine kinase inhibitors. Agents such as ibrutinib and zanubrutinib interfere with signaling required for malignant B-cell survival. These forms of targeted cancer therapy are generally administered continuously rather than as a fixed course.
- Proteasome inhibitor–based combinations. Bortezomib-containing regimens are used in selected settings.
Regimen selection depends on disease manifestations, molecular findings, other illnesses, adverse-effect profiles, previous treatment, and whether a fixed-duration or continuous approach is appropriate. Conventional chemotherapy and targeted agents have different toxicity patterns; relevant risks include infection, cytopenias, neuropathy, bleeding, hypertension, and cardiac arrhythmias, depending on the agent.
Rituximab can cause a temporary rise in serum IgM, known as an IgM flare. This does not necessarily indicate disease progression but can worsen viscosity-related complications.
Plasma exchange and supportive care
Therapeutic plasma exchange, a form of apheresis, rapidly removes circulating IgM and is used for symptomatic hyperviscosity. Its effect is temporary because it does not eliminate the malignant clone; systemic treatment addresses ongoing IgM production.
Supportive care addresses anemia, infection risk, neuropathy, and other complications. Autologous hematopoietic stem-cell transplantation is used infrequently, mainly in selected patients with relapsed disease.
Course and prognosis
WM usually follows a chronic, relapsing course. Standard treatments can produce prolonged disease control but are not generally considered curative. Some asymptomatic patients remain untreated for years.
Prognosis varies with age, blood counts, biochemical findings, disease complications, and treatment response. Prognostic scoring systems estimate outcomes in patient groups but do not determine an individual course. Survival estimates also depend on the treatment era and on deaths from illnesses unrelated to WM.
A minority of cases transform into an aggressive lymphoma, most often diffuse large B-cell lymphoma. Rapidly enlarging lymph nodes, new systemic symptoms, or an abrupt change in disease behavior can prompt investigation; tissue biopsy is generally required to establish transformation.